Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico Milano is valid for three years with the possibility of a one-year extension. The…
On Tuesday July 23 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q2 2024 report (which will have been published earlier on July 23 at 07.30 a.m. CET).…
Devyser has secured a tender for its NGS product, Devyser Thalassemia, which is designed for screening and confirmation of thalassemia, a hereditary blood disorder. The tender, with a…
Devyser Diagnostics AB (publ) today announced that the company has expanded its exclusive collaboration and distribution agreement with Thermo Fisher Scientific, giving Thermo Fisher…
Devyser is proud to announce that its Y-chromosomal microdeletion test, Devyser AZF Extension, has been updated in accordance with the latest 2023 guidelines set by the European Molecular…
Devyser was awarded a five-year extension tender with the Toscana region in Italy for ten of its products. Devyser has also, via its distribution partner, been awarded the transplantation…
Devyser was awarded a tender in Italy for some of its oncology NGS solutions. The tender with the University Hospital of Bologna is valid for two years with the potential of a one-year…
Devyser was awarded a tender for its NGS product Devyser Thalassemia, which is used for screening and confirmation of thalassemia, a hereditary blood disorder. The tender with Instituto…
The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Tuesday, 14 May 2024 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed…
“Devyser reports continued strong sales growth and high gross margins for the quarter. It is particularly pleasing to see that our investment in the Americas is continuing to produce…
